William John Robinson
Directeur/Membre du Conseil chez Cycle Pharmaceuticals Ltd.
Profil
William John Robinson is currently a Director at Cycle Pharmaceuticals Ltd.
He previously worked as a Director at Shionogi Pharma, Inc. from 2004 to 2008, a Non-Executive Director at Plethora Solutions Holdings Plc from 2007 to 2013, and as Vice President-Sales & Marketing at Eli Lilly & Co. from 1976 to 2004.
He also held the position of Executive Vice President-Global Operations at UCB Celltech.
Postes actifs de William John Robinson
| Sociétés | Poste | Début |
|---|---|---|
Cycle Pharmaceuticals Ltd.
 Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Directeur/Membre du Conseil | 01/11/2013 |
Anciens postes connus de William John Robinson
| Sociétés | Poste | Fin |
|---|---|---|
| PLETHORA SOLUTIONS HOLDINGS PLC | Président | 12/04/2013 |
Shionogi Pharma, Inc.
 Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | Directeur/Membre du Conseil | 09/10/2008 |
| ELI LILLY AND COMPANY | Sales & Marketing | 01/01/2004 |
UCB Celltech
 UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The company is based in Slough, UK and was founded in 2006. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | Health Technology |
Plethora Solutions Holdings Plc
 Plethora Solutions Holdings Plc Pharmaceuticals: MajorHealth Technology Plethora Solutions Holdings Plc operates as a pharmaceutical company. It engages in the development and marketing of products for the treatment and management of urological disorders. The firm operates through the Plethora Development and The Urology Co. segments. The Plethora Development segment develops new pharmaceutical products. The Urology Co. segment sells and markets pharmaceutical and healthcare products. The company was founded by Michael Grant Wyllie and Neil Brent Stafford in December 2003 and is headquartered in Chalgrove, the United Kingdom. | Health Technology |
UCB Celltech
UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The company is based in Slough, UK and was founded in 2006. | Health Technology |
Cycle Pharmaceuticals Ltd.
Cycle Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cycle Pharmaceuticals Ltd. is a British privately-owned biotechnology company that focuses on delivering drug treatments and services to the under-served rare disease patient community. The company is based in Cambridge, UK, and their mission is to utilize the latest pharmaceutical technologies to deliver superior drug treatments to better serve rare genetic disease patients. The company specializes in rare metabolic, immunological, and neurological genetic conditions. The company also provides individualized patient support services to meet patient needs swiftly. Cycle Pharmaceuticals works with a variety of partners to support their patients' needs through their named patient program. | Health Technology |
